EMILY HARSH: Open Payments
NPI 1467207662 · SEYMOUR, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,406 in 74 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $547 · 2025 $1,406
Food & beverage: $1,406
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $297 |
| AstraZeneca Pharmaceuticals LP | 7 | $172 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $153 |
| Novartis Pharmaceuticals Corporation | 6 | $120 |
| Lilly USA, LLC | 8 | $117 |
| ABBVIE INC. | 5 | $84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $83 |
| Merck Sharp & Dohme LLC | 4 | $68 |
| Lundbeck LLC | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
Products named: Ozempic, Kerendia, JARDIANCE, REXULTI, LEQVIO, MOUNJARO, VRAYLAR, Rybelsus.
Industry payments across IN — which companies pay providers there.
